Killer cell lectin-like receptor subfamily G member 1 (KLRG1), a type II transmembrane protein, was identified as an inhibitory receptor expressed on natural killer (NK) cells and certain T cells. The protein regulates effector functions and developmental processes in these cells. In this study, we established a specific and sensitive monoclonal antibody (mAb) for human KLRG1 (hKLRG1), which is useful for flow cytometry, using a Cell-Based Immunization and Screening (CBIS) method. The established anti-hKLRG1 mAb, KLMab-1 (mouse IgG1, kappa), reacted with overexpressed hKLRG1 in Chinese hamster ovary-K1 (CHO/hKLRG1) and human NK cells, which also expressed endogenous hKLRG1 as confirmed by flow cytometry. KLMab-1, which was established by the CBIS method, could be useful for elucidating the hKLRG1-related biological response by flow cytometry.
Get full access to this article
View all access options for this article.
References
1.
TimonenT, and SakselaE: Isolation of human NK cells by density gradient centrifugation. J Immunol Methods, 1980; 36:285–291.
2.
BerringtonJE, BargeD, FentonAC, CantAJ, and SpickettGP: Lymphocyte subsets in term and significantly preterm UK infants in the first year of life analysed by single platform flow cytometry. Clin Exp Immunol, 2005; 140:289–292.
3.
PegramHJ, AndrewsDM, SmythMJ, DarcyPK, and KershawMH: Activating and inhibitory receptors of natural killer cells. Immunol Cell Biol, 2011; 89:216–224.
4.
LanierLL: NK cell recognition. Annu Rev Immunol, 2005; 23:225–274.
5.
HankeT, CorralL, VanceRE, and RauletDH: 2F1 antigen, the mouse homolog of the rat “mast cell function-associated antigen,” is a lectin-like type II transmembrane receptor expressed by natural killer cells. Eur J Immunol, 1998; 28:4409–4417.
6.
RobbinsSH, NguyenKB, TakahashiN, MikayamaT, BironCA, and BrossayL: Cutting edge: Inhibitory functions of the killer cell lectin-like receptor G1 molecule during the activation of mouse NK cells. J Immunol, 2002; 168:2585–2589.
7.
BlaserC, KaufmannM, and PircherH: Virus-activated CD8 T cells and lymphokine-activated NK cells express the mast cell function-associated antigen, an inhibitory C-type lectin. J Immunol, 1998; 161:6451–6454.
8.
HoylerT, KloseCS, SouabniA, Turqueti-NevesA, PfeiferD, RawlinsEL, VoehringerD, BusslingerM, and DiefenbachA: The transcription factor GATA-3 controls cell fate and maintenance of type 2 innate lymphoid cells. Immunity, 2012; 37:634–648.
9.
SalimiM, BarlowJL, SaundersSP, XueL, Gutowska-OwsiakD, WangX, HuangLC, JohnsonD, ScanlonST, McKenzieAN, FallonPG, OggGS: A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis. J Exp Med, 2013; 210:2939–2950.
10.
ChengG, YuanX, TsaiMS, PodackER, YuA, and MalekTR: IL-2 receptor signaling is essential for the development of Klrg1+ terminally differentiated T regulatory cells. J Immunol, 2012; 189:1780–1791.
11.
GründemannC, BauerM, SchweierO, von OppenN, LässingU, SaudanP, BeckerKF, KarpK, HankeT, BachmannMF, and PircherH: Cutting edge: Identification of E-cadherin as a ligand for the murine killer cell lectin-like receptor G1. J Immunol, 2006; 176:1311–1315.
12.
ItoM, MaruyamaT, SaitoN, KoganeiS, YamamotoK, and MatsumotoN: Killer cell lectin-like receptor G1 binds three members of the classical cadherin family to inhibit NK cell cytotoxicity. J Exp Med, 2006; 203:289–295.
13.
SchwartzkopffS, GründemannC, SchweierO, RosshartS, KarjalainenKE, BeckerKF, and PircherH: Tumor-associated E-cadherin mutations affect binding to the killer cell lectin-like receptor G1 in humans. J Immunol, 2007; 179:1022–1029.
14.
HensonSM, and AkbarAN: KLRG1—more than a marker for T cell senescence. Age (Dordr), 2009; 31:285–291.
15.
RosshartS, HofmannM, SchweierO, PfaffAK, YoshimotoK, TakeuchiT, MolnarE, SchamelWW, and PircherH: Interaction of KLRG1 with E-cadherin: New functional and structural insights. Eur J Immunol, 2008; 38:3354–3364.
16.
GreenbergSA, KongSW, ThompsonE, and GullaSV: Co-inhibitory T cell receptor KLRG1: Human cancer expression and efficacy of neutralization in murine cancer models. Oncotarget, 2019; 10:1399–1406.
17.
NishimuraH, NoseM, HiaiH, MinatoN, and HonjoT: Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity, 1999; 11:141–151.
18.
NishimuraH, MinatoN, NakanoT, and HonjoT: Immunological studies on PD-1 deficient mice: Implication of PD-1 as a negative regulator for B cell responses. Int Immunol, 1998; 10:1563–1572.
19.
EngelhardtJJ, SullivanTJ, and AllisonJP: CTLA-4 overexpression inhibits T cell responses through a CD28-B7-dependent mechanism. J Immunol, 2006; 177:1052–1061.
20.
SharmaP, and AllisonJP: The future of immune checkpoint therapy. Science, 2015; 348:56–61.
HodiFS, O'DaySJ, McDermottDF, WeberRW, SosmanJA, HaanenJB, GonzalezR, RobertC, SchadendorfD, HasselJC, AkerleyW, van den EertweghAJ, LutzkyJ, LoriganP, VaubelJM, LinetteGP, HoggD, OttensmeierCH, LebbéC, PeschelC, QuirtI, ClarkJI, WolchokJD, WeberJS, TianJ, YellinMJ, NicholGM, HoosA, and UrbaWJ: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med, 2010; 363:711–723.
23.
YamadaS, ItaiS, NakamuraT, YanakaM, SaidohN, ChangYW, HandaS, HaradaH, KagawaY, IchiiO, KonnaiS, KanekoMK, and KatoY: PMab-52: Specific and sensitive monoclonal antibody against cat podoplanin for immunohistochemistry. Monoclon Antib Immunodiagn Immunother, 2017; 36:224–230.
24.
ItaiS, FujiiY, NakamuraT, ChangYW, YanakaM, SaidohN, HandaS, SuzukiH, HaradaH, YamadaS, KanekoMK, and KatoY: Establishment of CMab-43, a sensitive and specific anti-CD133 monoclonal antibody, for immunohistochemistry. Monoclon Antib Immunodiagn Immunother, 2017; 36:231–235.
25.
FujiiY, KanekoM, NeyazakiM, NogiT, KatoY, and TakagiJ: PA tag: A versatile protein tagging system using a super high affinity antibody against a dodecapeptide derived from human podoplanin. Protein Expr Purif, 2014; 95:240–247.
26.
FurusawaY, KanekoMK, and KatoY: Establishment of an anti-CD20 monoclonal antibody (C(20)Mab-60) for immunohistochemical analyses. Monoclon Antib Immunodiagn Immunother, 2020; 39:112–116.
27.
YamadaS, ItaiS, NakamuraT, YanakaM, KanekoMK, and KatoY: Detection of high CD44 expression in oral cancers using the novel monoclonal antibody, C(44)Mab-5. Biochem Biophys Rep, 2018; 14:64–68.
SayamaY, KanekoMK, TakeiJ, HosonoH, SanoM, AsanoT, and KatoY: Establishment of a novel anti-TROP2 monoclonal antibody TrMab-29 for immunohistochemical analysis. Biochem Biophys Rep, 2021; 25:100902.
30.
BoerMC, van MeijgaardenKE, GolettiD, VaniniV, PrinsC, OttenhoffTH, and JoostenSA: KLRG1 and PD-1 expression are increased on T-cells following tuberculosis-treatment and identify cells with different proliferative capacities in BCG-vaccinated adults. Tuberculosis (Edinb), 2016; 97:163–171.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
